Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review,        editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name
E-mail
Phone
Title
Content
Verification Code
x Close Forever Close
Volume 31 Issue 5
. 
Turn off MathJax
Article Contents
Article Navigation >  Journal of Pharmaceutical Practice and Service  > 2013  >  31(5): 388-389

Wu Ya-miao. Cost-minimization analysis of joint venture entecavier and domestic entecavier in treating patients with chronic hepatitis B[J]. Journal of Pharmaceutical Practice and Service, 2013, 31(5): 388-389. doi: 10.3969/j.issn.1006-0111.2013.05.021
Citation: Wu Ya-miao. Cost-minimization analysis of joint venture entecavier and domestic entecavier in treating patients with chronic hepatitis B[J]. Journal of Pharmaceutical Practice and Service, 2013, 31(5): 388-389. doi: 10.3969/j.issn.1006-0111.2013.05.021
shu

Cost-minimization analysis of joint venture entecavier and domestic entecavier in treating patients with chronic hepatitis B

doi: 10.3969/j.issn.1006-0111.2013.05.021

  • Department of Pharmacy, Ningbo NO.2 Hospital, Ningbo 315010, China

  • Received Date: 2012-11-17
  • Rev Recd Date: 2013-05-09
  • Objective To study the validity and affordability between joint venture entercavier and domestic entercavier in treating patients with chronic hepatitis B. Methods 65 patients with chronic hepatitis B were select who were treated with entercavier between Oct. 2009 to Oct.2010 in Ningbo No. 2 Hospital expert outpatient service. These patients were divide into group A (33 cases) and B(32 cases). Group A was treated with joint venture entecavier and group B was treated with domestic ones. all patients were given 0.5 mg daily and treated for 48 weeks. The cost-minimization analysis was made between two groups. Results ALT recovery rate, HBV-DNA negative conversion rate and HBeAg serum conversion rate had no statistically significant between two groups (P>0.05), but the cost of group A was 12 028.8, and the cost of group B was 7 996.8. Conclusions The domestic entecavier was better than the joint venture entecavier in treating the patients with chronic hepatitis B by cost-minimization analysis.
  • [1] 拉米夫定临床应用专家.2004年拉米夫定临床应用专家组共识[J].中华肝脏病杂志,2004,12(7):425.
    [2] 中华医学会肝病学分会、中华医学会感染病学分会.慢性乙型肝炎防治指南[J].中华肝脏病杂志,2005,13(12):881.
    [3] 冯 璇,童东梅,徐 翔.三种钙通道阻滞剂治疗高血压的费用效果-分析[J].中国临床药理学与治疗学,2001,6(3):233.
    [4] 顾 海,李洪超.药物经济学成本-效果分析应用的相关问题探讨[J].中国药房,2004,15(11):674.
    [5] 赵 东,朱玉霞.三种降压药物治疗方案的成本-效果分析[J].中国医院药学杂志 2005,25(8):753.
    [6] 刘林华,陈新月.抗乙型肝炎病毒新药-恩替卡韦[J].国际流行病学传染病学杂志,2006,33(1):58.
  • 加载中
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索
Get Citation
PDF
XML

Article Metrics

Article views(2690) PDF downloads(379) Cited by()

Related
Proportional views

Cost-minimization analysis of joint venture entecavier and domestic entecavier in treating patients with chronic hepatitis B

doi: 10.3969/j.issn.1006-0111.2013.05.021
  • Department of Pharmacy, Ningbo NO.2 Hospital, Ningbo 315010, China
  • Received Date: 2012-11-17
  • Rev Recd Date: 2013-05-09

Abstract: Objective To study the validity and affordability between joint venture entercavier and domestic entercavier in treating patients with chronic hepatitis B. Methods 65 patients with chronic hepatitis B were select who were treated with entercavier between Oct. 2009 to Oct.2010 in Ningbo No. 2 Hospital expert outpatient service. These patients were divide into group A (33 cases) and B(32 cases). Group A was treated with joint venture entecavier and group B was treated with domestic ones. all patients were given 0.5 mg daily and treated for 48 weeks. The cost-minimization analysis was made between two groups. Results ALT recovery rate, HBV-DNA negative conversion rate and HBeAg serum conversion rate had no statistically significant between two groups (P>0.05), but the cost of group A was 12 028.8, and the cost of group B was 7 996.8. Conclusions The domestic entecavier was better than the joint venture entecavier in treating the patients with chronic hepatitis B by cost-minimization analysis.

Wu Ya-miao. Cost-minimization analysis of joint venture entecavier and domestic entecavier in treating patients with chronic hepatitis B[J]. Journal of Pharmaceutical Practice and Service, 2013, 31(5): 388-389. doi: 10.3969/j.issn.1006-0111.2013.05.021
Citation: Wu Ya-miao. Cost-minimization analysis of joint venture entecavier and domestic entecavier in treating patients with chronic hepatitis B[J]. Journal of Pharmaceutical Practice and Service, 2013, 31(5): 388-389. doi: 10.3969/j.issn.1006-0111.2013.05.021
shu

    HTML

Reference (6)

Catalog

    版权所有：《药学实践与服务》编辑委员会

    Supervisor & Sponsors: Address: No 325 Guohe Road, ShanghaiPost Code: 200433

    Tel: （021）81871324,81871397 E-mail: yxsjzzs@163.com

    网站备案号 沪ICP备05003363号-1

    Supported by: Beijing Renhe Information Technology Co., Ltd.  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return